Search results for "Predictive marker"

showing 10 items of 31 documents

Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients

2011

Background\ud Receptor activator of NFkB (RANK), its ligand (RANKL) and the decoy receptor of RANKL (osteoprotegerin, OPG) play a pivotal role in bone remodeling by regulating osteoclasts formation and activity. RANKL stimulates migration of RANK-expressing tumor cells in vitro, conversely inhibited by OPG.\ud \ud Materials and Methods\ud We examined mRNA expression levels of RANKL/RANK/OPG in a publicly available microarray dataset of 295 primary breast cancer patients. We next analyzed RANK expression by immunohistochemistry in an independent series of 93 primary breast cancer specimens and investigated a possible association with clinicopathological parameters, bone recurrence and surviv…

Anatomy and PhysiologyMicroarraysSettore MED/06 - Oncologia MedicaCancer TreatmentLigandsMetastasisBone remodelingMetastasisBasic Cancer ResearchBreast TumorsBone and Soft Tissue SarcomasNeoplasm MetastasisMusculoskeletal SystemOligonucleotide Array Sequence AnalysisMultidisciplinaryPredictive markerReceptor Activator of Nuclear Factor-kappa BQRBone metastasisMiddle AgedImmunohistochemistryGene Expression Regulation NeoplasticOncologyRANKLMedicineFemaleResearch Articlemusculoskeletal diseasesmedicine.medical_specialtyHistologyScienceBone NeoplasmsBreast NeoplasmsBiologyBreast cancerAntibody TherapySDG 3 - Good Health and Well-beingOsteoprotegerinInternal medicinemedicineHumansRNA MessengerBoneBiologyAgedBreast cancer bone metastasis RANK-RANKLRANK LigandOsteoprotegerinComputational BiologyCancers and NeoplasmsRANK Ligandmedicine.diseaseEndocrinologyCancer researchbiology.protein
researchProduct

A Multicenter Large Retrospective Database on the Personalization of Stereotactic Ablative Radiotherapy for Lung Metastases From Colon-Rectal Cancer:…

2021

PURPOSE/OBJECTIVE(S): stereotactic ablative radiotherapy (SABR) has been shown to increase survival rates in oligometastatic disease (OMD), but local control of colorectal metastases still remains poor. We aimed to identify potential predictive factors of SBRT response through a multicenter large retrospective database and to investigate how lung SBRT can impact on the progression to the polymetastatic disease (PMD). MATERIALS/METHODS: the study involved 22 centers, and was approved by the Ethical Committee (Prot. Negrar 2019-ZT). 1023 lung metastases treated with SBRT in 622 patients were reported. The median BED was 105 Gy10. Lesion diameter GTV, PTV volume, dose, fractionations, and site…

Cancer ResearchUnivariate analysismedicine.medical_specialtyRadiationPredictive markerColorectal cancerbusiness.industrymedicine.medical_treatmentmedicine.disease_causemedicine.diseaseSABR volatility modelPrimary tumorRadiation therapyLesioncolorectal metastaseOncologymedicineRadiology Nuclear Medicine and imagingKRASRadiologyoligometastasemedicine.symptombusinessSABRInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

343 External validation of tumour-free distance as novel prognostic marker in early-stage cervical cancer undergoing primary surgery

2020

Introduction Tumor-free distance (TFD), defined as the minimum distance of uninvolved stroma between the tumor and peri-cervical stromal ring, was recently proposed as predictive marker of recurrence in patients with early-stage cervical cancer treated by primary surgery (particularly if ≤3.5 mm). The aims of the present study were to assess the prognostic value of TFD and to compare TFD with other known prognostic markers in early-stage cervical cancer. Methods Patients with pathologic FIGO 2009 stage IA1-IIB cervical cancer, treated by primary radical surgical treatment between 01/2000 and 12/2018, were retrospectively included. Adjuvant treatment was administered according to the presenc…

Cervical cancermedicine.medical_specialtyMultivariate analysisPredictive markerHysterectomyParametrialbusiness.industrymedicine.medical_treatmentExternal validationmedicine.diseaseSurgeryLaparotomymedicineStage (cooking)businessPoster
researchProduct

From Molecular Tumor Diagnostics to Individualized Treatment with Phytochemicals Derived from Chinese Herbs

2011

ChemotherapyPredictive markerbiologymedicine.medical_treatmentIndividualized treatmentChinese herbsPharmacologyBiochemistryMultiple drug resistanceGeneticsbiology.proteinmedicineMolecular MedicineEpidermal growth factor receptorBiotechnologyP-glycoproteinForum on Immunopathological Diseases and Therapeutics
researchProduct

Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker

2007

Survivin functions as an apoptosis inhibitor and a regulator of cell division in many tumours. The intracellular localization of survivin in tumours has been suggested as a prognostic marker. However, current reports are inconsistent and the underlying molecular mechanisms are not understood. The present study has examined the localization and prognostic value of nuclear and cytoplasmic survivin in the pre-therapeutic biopsies from 71 oral and oropharyngeal squamous carcinoma (OSCC) patients. Statistical analysis indicated that preferential nuclear versus cytoplasmic survivin correlated with favourable versus unfavourable disease outcome. Uni- and multi-variate analysis showed that in contr…

CytoplasmProgrammed cell deathPathologymedicine.medical_specialtySurvivinReceptors Cytoplasmic and NuclearApoptosisKaplan-Meier EstimateCysteine Proteinase InhibitorsKaryopherinsInhibitor of Apoptosis ProteinsPathology and Forensic MedicineCell Line TumorSurvivinBiomarkers TumorCarcinomaHumansMedicineNuclear export signalneoplasmsCell NucleusNuclear Export SignalsPredictive markerbusiness.industryCell cyclePrognosismedicine.diseaseImmunohistochemistryNeoplasm ProteinsSquamous carcinomaOropharyngeal NeoplasmsHead and Neck NeoplasmsApoptosisCarcinoma Squamous CellCancer researchMouth NeoplasmsbusinessMicrotubule-Associated ProteinsThe Journal of Pathology
researchProduct

Modulation of Irisin and Physical Activity on Executive Functions in Obesity and Morbid obesity

2016

Whether the executive profile is different between obesity (OB) and morbid obesity (MO) remains unclear. Recent evidence suggests that physical activity (PA) can act as a cognitive enhancer. Irisin is a recently discovered hormone associated with some of the positive effects of PA. The objective of the study was to investigate the executive profile in OB and MO, and to explore the role of PA and irisin. 114 participants were included (21 OB, 44 MO and 49 healthy controls-HC) in the study and assessed with the Wisconsin Card Sorting Test, Stroop Color and Word Test, and Iowa Gambling Task. All participants were female, aged between 18 and 60 years. Results showed a similar dysfunctional prof…

DecisionObesitat mòrbida -- TractamentMorbid obesity0302 clinical medicineWisconsin Card Sorting TestObesity -- TreatmentMorbid obesity -- TreatmentMultidisciplinaryNeuropsychologyExercici -- Aspectes fisiològicsCognitionMiddle AgedExecutive functionsObesity MorbidObesitat -- TractamentCognitive controlObesitatFemaleClinical psychologyAdultIrisinmedicine.medical_specialtyAdolescentDecision MakingObesitat mòrbidaDysfunctional profile030209 endocrinology & metabolismDysfunctional familyPredictive markersArticle03 medical and health sciencesInternal medicinemedicineHumansObesityExercisePhysical activitybusiness.industryPhysical fitnessmedicine.diseaseObesityIowa gambling taskHormonesFibronectinsEndocrinologybusinessDecision making030217 neurology & neurosurgeryStroop effectCondició físicaScientific Reports
researchProduct

Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients.

2018

Background Heart failure (HF) is associated with a high rate of readmissions within 30 days post-discharge and in the following year, especially in frail elderly patients. Biomarker data are scarce in this high-risk population. This study assessed the value of early post-discharge circulating levels of ST2, NT-proBNP, CA125, and hs-TnI for predicting 30-day and 1-year outcomes in comorbid frail elderly patients with HF with mainly preserved ejection fraction (HFpEF). Methods Blood samples were obtained at the first visit shortly after discharge (4.9 ± 2 days). The primary endpoint was the composite of all-cause mortality or HF-related rehospitalization at 30 days and at 1 year. All-cause mo…

Malemedicine.medical_specialtyFrail ElderlyPopulationComorbidity030204 cardiovascular system & hematologylcsh:GeriatricsPatient Readmission03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineCause of DeathNatriuretic Peptide BrainClinical endpointmedicineHumans030212 general & internal medicineProspective StudieseducationProspective cohort studyAgedAged 80 and overHeart Failureeducation.field_of_studyPredictive markerSurrogate endpointbusiness.industryHazard ratioMembrane Proteinsmedicine.diseasePrognosisComorbidityPeptide Fragmentslcsh:RC952-954.6CA-125 AntigenBiomarker (medicine)FemaleGeriatrics and GerontologybusinessBiomarkersResearch ArticleFollow-Up Studies
researchProduct

Immuno-inflammatory and thrombotic/fibrinolytic variables associated with acute ischemic stroke diagnosis.

2008

Abstract Introduction Accumulating evidence suggests that inflammation plays an important role in the development of acute cerebrovascular disease. The aim of this study is to evaluate the predictive value of a series of candidate serum immuno-inflammatory and thrombotic/fibrinolitic molecules towards diagnosis of acute ischemic stroke. Materials and methods We enrolled 120 consecutive patients with a diagnosis of acute ischemic stroke and 123 consecutive hospitalized control patients without a diagnosis of acute ischemic stroke. We evaluated plasma levels of IL-1β, TNF-β, IL-6 and IL-10, E-selectin, P-selectin, sICAM-1 and sVCAM-1 as markers of immuno-inflammatory activation, vWF plasma le…

Malemedicine.medical_specialtyPathologySettore MED/09 - Medicina Internamedicine.medical_treatmentImmuno-inflammatory thrombotic/fibrinolytic acute ischemic strokeBrain IschemiaBrain ischemiaPredictive Value of TestsRisk FactorsInternal medicineFibrinolysisstroke inflammation predictive markersmedicineHumansEndothelial dysfunctionStrokeAgedAged 80 and overInflammationVascular diseasebusiness.industryCerebral infarctionFibrinolysisBrainThrombosisMiddle Agedmedicine.diseaseThrombosisStrokeROC CurveImmune SystemPredictive value of testsCardiologyFemaleCardiology and Cardiovascular Medicinebusiness
researchProduct

Abstract 448: Molecular analysis of BRAF gene and PTEN gene expression in metastatic colorectal cancer patients: Feasibility study

2014

Abstract Introduction There are numerous causes triggering CRC. 25-80% of CRC shown a deregulation in Epidermal Growth Factor Receptor (EGFR) pathway. Two signaling pathways downstream of the EGFR are dysregulated in CRC the mitogen-activated protein kinase (MAPK) and the phosphoinositide-3-kinase (PI3K) pathway. Activating mutations in KRAS and BRAF (MAPK pathway) and PIK3CA affect prognosis and/or response to anti-EGFR MoAb. PTEN is a downstream effector of EGFR pathway and is involved in PI3K pathway. Loss of PTEN protein expression can occur through epigenetic silencing and mutation or allelic loss. Immunohistochemistry (IHC) is the most effective way to assay for loss of PTEN expressio…

Neuroblastoma RAS viral oncogene homologCancer ResearchPredictive markerbiologyColorectal cancerCancermedicine.diseasemedicine.disease_causeOncologyCancer researchTaqManmedicinebiology.proteinPTENKRASPI3K/AKT/mTOR pathwayCancer Research
researchProduct

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations

2018

Background: The present study investigated the efficacy and safety of nivolumab in pre-treated patients with advanced NSCLC harbouring KRAS mutations. Methods: Clinical data and KRAS mutational status were analysed in patients treated with nivolumab within the Italian Expanded Access Program. Objective response rate, progression-free survival and overall survival were evaluated. Patients were monitored for adverse events using the National Cancer Institute Common Terminology Criteria for Adverse Events. Results: Among 530 patients evaluated for KRAS mutations, 206 (39%) were positive while 324 (61%) were KRAS wild-type mutations. KRAS status did not influence nivolumab efficacy in terms of …

OncologyAdultMalemedicine.medical_specialtyCancer Researchmedicine.disease_causePredictive markersArticleProto-Oncogene Proteins p21(ras)03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungmedicineCarcinoma80 and overHumansProgression-free survivalLung cancerNon-Small-Cell LungneoplasmsAgedAged 80 and overbusiness.industryCarcinomaCancerCommon Terminology Criteria for Adverse EventsMiddle Agedmedicine.diseasedigestive system diseasesProgression-Free Survivalrespiratory tract diseasesNivolumabOncologyAdult; Aged; Aged 80 and over; Carcinoma Non-Small-Cell Lung; Female; Humans; Male; Middle Aged; Mutation; Nivolumab; Progression-Free Survival; Proto-Oncogene Proteins p21(ras); ImmunotherapyOncology; Cancer Research030220 oncology & carcinogenesisExpanded accessMutationFemaleKRASImmunotherapyNivolumabbusinessNon-small-cell lung cancer
researchProduct